Publications

Detailed Information

Simvastatin plus irinotecan, 5-fluorouracil, and leucovorin (FOLFIRI) as first-line chemotherapy in metastatic colorectal patients: a multicenter phase II study

DC Field Value Language
dc.contributor.authorLee, Jeeyun-
dc.contributor.authorJung, Kyung Hae-
dc.contributor.authorPark, Young Suk-
dc.contributor.authorAhn, Joong Bae-
dc.contributor.authorShin, Sang Jun-
dc.contributor.authorIm, Seock-Ah-
dc.contributor.authorOh, Do Youn-
dc.contributor.authorShin, Dong Bok-
dc.contributor.authorKim, Tae Won-
dc.contributor.authorLee, Namsu-
dc.contributor.authorByun, Jae Ho-
dc.contributor.authorHong, Yong Sang-
dc.contributor.authorPark, Joon Oh-
dc.contributor.authorPark, Se Hoon-
dc.contributor.authorLim, Ho Yeong-
dc.contributor.authorKang, Won Ki-
dc.date.accessioned2012-05-24T02:09:37Z-
dc.date.available2012-05-24T02:09:37Z-
dc.date.created2021-11-23-
dc.date.created2021-11-23-
dc.date.issued2009-09-
dc.identifier.citationCancer Chemotherapy and Pharmacology, Vol.64 No.4, pp.657-663-
dc.identifier.issn0344-5704-
dc.identifier.other148337-
dc.identifier.urihttps://hdl.handle.net/10371/76385-
dc.description.abstractSimvastatin has demonstrated anti-tumor activity in preclinical studies via tumor cell senescence, anti-angiogenesis, and apoptosis. This phase II trial evaluated the efficacy and toxicity profile of conventional FOLFIRI chemotherapy plus simvastatin in metastatic colorectal cancer patients. Patients received irinotecan 180 mg/m(2) as a 90-min infusion followed by leucovorin 200 mg/m(2) in a 2-h infusion, and then 5-FU 400 mg/m(2) bolus injection followed by 2,400 mg/m(2) as a 46-h continuous infusion. Treatment cycles were repeated every 2 weeks until documented disease progression, unacceptable toxicity, or patient's refusal. Simvastatin 40 mg tablet was given once daily per oral everyday during the period of chemotherapy without a rest. From October 2005 to June 2006, 49 patients were enrolled. The overall response rate (ORR) was 46.9% (95% CI, 31.0-58.8) by intent-to-treat analysis and 45.8% (95% CI, 33.3-62.8) by per-protocol analysis. There were one complete response (CR) and 22 partial responses (PRs). Both CR and PRs were confirmed at least 4 weeks later. The disease-control rate was 83.7% (95% CI, 73.4-94.0). The median follow-up duration was 25.6 months (range, 20.9-28.8 months). The median survival of all patients was 21.8 months (95% CI, 14.4, 29.2). The median TTP was 9.9 months (95% CI, 6.4, 13.3). No patients experienced additional adverse effect that was definitely caused by simvastatin drug therapy in this trial. The combination of simvastatin plus FOLFIRI was a feasible regimen with promising antitumor activity.-
dc.language영어-
dc.language.isoenko_KR
dc.publisherSpringer Verlag-
dc.titleSimvastatin plus irinotecan, 5-fluorouracil, and leucovorin (FOLFIRI) as first-line chemotherapy in metastatic colorectal patients: a multicenter phase II study-
dc.typeArticle-
dc.contributor.AlternativeAuthor임석아-
dc.identifier.doi10.1007/s00280-008-0913-5-
dc.citation.journaltitleCancer Chemotherapy and Pharmacology-
dc.description.citedreferenceKarapetis CS, 2008, NEW ENGL J MED, V359, P1757-
dc.description.citedreferenceXiao H, 2008, INT J CANCER, V123, P983, DOI 10.1002/ijc.23718-
dc.description.citedreferenceVinogradova Y, 2007, GASTROENTEROLOGY, V133, P393, DOI 10.1053/j.gastro.2007.05.023-
dc.description.citedreferenceSetoguchi S, 2007, CIRCULATION, V115, P27, DOI 10.1161/CIRCULATIONAHA.106.650176-
dc.description.citedreferenceLee J, 2006, BIOCHEM BIOPH RES CO, V339, P748, DOI 10.1016/j.bbrc.2005.11.075-
dc.description.citedreferenceDulak J, 2005, CURR CANCER DRUG TAR, V5, P579-
dc.description.citedreferenceColucci G, 2005, J CLIN ONCOL, V23, P4866, DOI 10.1200/JCO.2005.07.113-
dc.description.citedreferencePoynter JN, 2005, NEW ENGL J MED, V352, P2184, DOI 10.1056/NEJMoa043792-
dc.description.citedreferenceGraaf MR, 2004, CANCER TREAT REV, V30, P609, DOI 10.1016/j.ctrv.2004.06.010-
dc.description.citedreferenceGraaf MR, 2004, J CLIN ONCOL, V22, P2388, DOI 10.1200/JCO.2004.02.027-
dc.description.citedreferenceTournigand C, 2004, J CLIN ONCOL, V22, P229, DOI 10.1200/JCO.2004.05.113-
dc.description.citedreferenceNUBEL T, 2004, FASEB J, V18, P140-
dc.description.citedreferenceSeeger H, 2003, EXP CLIN ENDOCR DIAB, V111, P47-
dc.description.citedreferenceChan KKW, 2003, CLIN CANCER RES, V9, P10-
dc.description.citedreferenceAlber HF, 2002, J AM COLL CARDIOL, V39, P1951-
dc.description.citedreferencePrueksaritanont T, 2002, DRUG METAB DISPOS, V30, P505-
dc.description.citedreferenceBelgore FM, 2001, AM J CARDIOL, V87, P805-
dc.description.citedreferenceKim WS, 2001, INVEST NEW DRUG, V19, P81-
dc.description.citedreferenceBELGORE FM, 2001, AM J CARDIOL, V87, pA9-
dc.description.citedreferenceBouterfa HL, 2000, ANTICANCER RES, V20, P2761-
dc.description.citedreferenceDouillard JY, 2000, LANCET, V355, P1041-
dc.description.citedreferenceTherasse P, 2000, J NATL CANCER I, V92, P205-
dc.description.citedreferenceAgarwal B, 1999, CLIN CANCER RES, V5, P2223-
dc.description.citedreferenceLarner J, 1998, AM J CLIN ONCOL-CANC, V21, P579-
dc.description.citedreferenceIyer L, 1998, J CLIN INVEST, V101, P847-
dc.description.citedreferenceRando RR, 1996, BIOCHEM SOC T, V24, P682-
dc.description.citedreferenceThibault A, 1996, CLIN CANCER RES, V2, P483-
dc.description.citedreferenceCASEY PJ, 1995, SCIENCE, V268, P221-
dc.description.citedreferenceSUMI S, 1994, PANCREAS, V9, P657-
dc.description.citedreferenceJAKOBISIAK M, 1991, P NATL ACAD SCI USA, V88, P3628-
dc.description.citedreferencePAN HY, 1990, J CLIN PHARMACOL, V30, P1128-
dc.description.citedreferenceGOLDSTEIN JL, 1990, NATURE, V343, P425-
dc.description.citedreferenceBOS JL, 1989, CANCER RES, V49, P4682-
dc.description.citedreferenceSIMON R, 1989, CONTROL CLIN TRIALS, V10, P1-
dc.description.citedreferenceKORNBRUST DJ, 1989, J PHARMACOL EXP THER, V248, P498-
dc.description.tc16-
dc.identifier.wosid000268479700002-
dc.identifier.scopusid2-s2.0-68149131593-
dc.citation.endpage663-
dc.citation.number4-
dc.citation.startpage657-
dc.citation.volume64-
dc.identifier.sci000268479700002-
dc.description.isOpenAccessN-
dc.contributor.affiliatedAuthorIm, Seock-Ah-
dc.contributor.affiliatedAuthorOh, Do Youn-
dc.type.docTypeArticle-
dc.description.journalClass1-
dc.subject.keywordPlusENDOTHELIAL GROWTH-FACTOR-
dc.subject.keywordPlusCANCER CELLS-
dc.subject.keywordPlusMEVALONATE PATHWAY-
dc.subject.keywordPlusRANDOMIZED-TRIAL-
dc.subject.keywordPlusLOVASTATIN-
dc.subject.keywordPlusSTATINS-
dc.subject.keywordPlusRISK-
dc.subject.keywordPlusGLUCURONIDATION-
dc.subject.keywordPlusPROLIFERATION-
dc.subject.keywordPlusINHIBITORS-
Appears in Collections:
Files in This Item:
There are no files associated with this item.

Related Researcher

  • College of Medicine
  • Department of Medicine
Research Area Clinical Medicine

Altmetrics

Item View & Download Count

  • mendeley

Items in S-Space are protected by copyright, with all rights reserved, unless otherwise indicated.

Share